The stock of Viveve Medical Inc (NASDAQ:VIVE) is a huge mover today! About 100,921 shares traded hands or 74.71% up from the average. Viveve Medical Inc (NASDAQ:VIVE) has risen 11.67% since March 4, 2016 and is uptrending. It has outperformed by 3.63% the S&P500.
The move comes after 6 months positive chart setup for the $72.03 million company. It was reported on Oct, 7 by Barchart.com. We have $18.74 PT which if reached, will make NASDAQ:VIVE worth $118.13M more.
Analysts await Viveve Medical Inc (NASDAQ:VIVE) to report earnings on November, 11. They expect $-0.41 EPS, up 43.06% or $0.31 from last year’s $-0.72 per share. After $-0.66 actual EPS reported by Viveve Medical Inc for the previous quarter, Wall Street now forecasts -37.88% EPS growth.
According to Zacks Investment Research, “Viveve Medical, Inc. is a medical device company focused on technologies for the cardiac and vascular markets. The Company’s lead product, RenalGuard (R), is designed to remove contrast dyes that are known to be toxic to the kidneys. Viveve Medical Inc., formerly known as PLC Systems Inc., is headquartered in Milford, Massachusetts.”
More notable recent Viveve Medical Inc (NASDAQ:VIVE) news were published by: Marketwatch.com which released: “Viveve Medical” on November 25, 2013, also Investorideas.com with their article: “Viveve Medical’s Treatment for Improving Women’s Sexual Function May Leapfrog …” published on October 05, 2016, Streetinsider.com published: “Form 424B3 VIVEVE MEDICAL, INC.” on September 22, 2016. More interesting news about Viveve Medical Inc (NASDAQ:VIVE) were released by: Streetinsider.com and their article: “Viveve Medical (VIVE) Reports Approval for Viveve System in Australia …” published on September 08, 2016 as well as Seekingalpha.com‘s news article titled: “Viveve Medical on deck for IPO” with publication date: May 25, 2016.
VIVE Company Profile
Viveve Medical, Inc., formerly PLC Systems, Inc., incorporated on March 1, 1999, designs, develops, makes and markets medical devices for the non-invasive treatment of vaginal laxity. The Company’s Viveve Treatment is a non-invasive solution for vaginal laxity that is performed in approximately 30 minutes, in a physician’s office. The Viveve System uses monopolar radiofrequency (RF) energy to generate low temperature heat. The vaginal mucosa is simultaneously cooled while this non-ablative heat is delivered into the submucosal layer. The RF energy stimulates the formation of collagen and causes the collagen fibers to remodel thereby tightening the submucosal tissue of the vaginal introitus. The RF stimulation causes subtle alterations in the collagen that can renew the tissue and further tighten the vaginal tissue over the next 1 to 3 months following treatment (the Viveve Treatment) and lead to increased sexual function.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.